The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Fisetin Attenuates Doxorubicin-Induced Cardiomyopathy In Vivo and In Vitro by Inhibiting Ferroptosis Through SIRT1/Nrf2 Signaling Pathway Activation
Open accessAbstract
Doxorubicin (DOX) is an anthracycline antibiotic that is used extensively for the management of carcinoma; however, its clinical application is limited due to its serious cardiotoxic side effects. Ferroptosis represents iron-dependent and reactive oxygen species (ROS)-related cell death and has been proven to contribute to the progression of DOX-induced cardiomyopathy. Fisetin is a natural flavonoid that is abundantly present in fruits and vegetables. It has been reported to exert cardioprotective effects against DOX-induced cardiotoxicity in experimental rats. However, the underlying mechanisms remain unknown. The present study investigated the cardioprotective role of fisetin and the underlying molecular mechanism through experiments in the DOX-induced cardiomyopathy rat and H9c2 cell models. The results revealed that fisetin treatment could markedly abate DOX-induced cardiotoxicity by alleviating cardiac dysfunction, ameliorating myocardial fibrosis, mitigating cardiac hypertrophy in rats, and attenuating ferroptosis of cardiomyocytes by reversing the decline in the GPX4 level. Mechanistically, fisetin exerted its antioxidant effect by reducing the MDA and lipid ROS levels and increasing the glutathione (GSH) level. Moreover, fisetin exerted its protective effect by increasing the SIRT1 expression and the Nrf2 mRNA and protein levels and its nuclear translocation, which resulted in the activation of its downstream genes such as HO-1 and FTH1. Selective inhibition of SIRT1 attenuated the protective effects of fisetin in the H9c2 cells, which in turn decreased the GSH and GPX4 levels, as well as Nrf2, HO-1, and FTH1 expressions. In conclusion, fisetin exerts its therapeutic effects against DOX-induced cardiomyopathy by inhibiting ferroptosis via SIRT1/Nrf2 signaling pathway activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903
Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732
Dietary polyphenols and the prevention of diseases
Scalbert, A., Manach, C., Morand, C., Rémésy, C., & Jiménez, L. (2005) · Critical Reviews in Food Science and Nutrition · doi:10.1080/1040869059096 · Cited by 2,999 · cited 1×
“, 2014) and protects against the oxidative stress-related degenerative diseases such as diabetes and cardiovascular diseases (Manach et al., 2005; Scalbert et al., 2005).”
BackgroundGlutathione: overview of its protective roles, measurement, and biosynthesis
Forman, H. J., Zhang, H., & Rinna, A. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.006 · Cited by 2,636
Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28251 · Cited by 2,012
Doxorubicin: The good, the bad and the ugly effect
Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803312 · Cited by 1,509 · cited 1×
“Doxorubicin (DOX), a highly effective antitumor anthracycline antibiotic derived from Streptomyces, is commonly used for the treatment of many types of malignancies, including solid tumors, breast cancer, soft tissue sarcomas, lymphomas, and leukemia (Carvalho et al., 2009).”
BackgroundFerrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models
Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., Rosenberg, P. A., Lo, D. C., Weinberg, J. M., Linkermann, A., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411006a · Cited by 1,146 · cited 1×
“Ferroptosis has been reported to be associated with various diseases, including glutamate-induced neuronal cell death and neurodegenerative diseases (Skouta et al., 2014; Yan and Zhang 2019), drug-induced liver injury (Lorincz et al.”
BackgroundHung, S.-C., Pochampally, R. R., Chen, S.-C., Hsu, S.-C., & Prockop, D. J. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0686 · Cited by 457
Ferroptosis is involved in acetaminophen induced cell death
Lőrincz, T., Jemnitz, K., Kardon, T., Mandl, J., & Szarka, A. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-015-9946-3 · Cited by 219
Cited by
GPX4, ferroptosis, and diseases
Zhang, W., Liu, Y., Liao, Y., Zhu, C., & Zou, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116512 · Cited by 426
Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism
Cui, Z., Zhao, X., Amevor, F. K., Du, X., Wang, Y., Li, D., Shu, G., Tian, Y., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943321 · Cited by 377
Self-citationOxidative Stress: Signaling Pathways, Biological Functions, and Disease
Liu, S., Liu, J., Wang, Y., Deng, F., & Deng, Z. (2025) · MedComm · doi:10.1002/mco2.70268 · Cited by 359
Wang, Z., Yao, M., Jiang, L., Wang, L., Yang, Y., Wang, Q., Qian, X., Zhao, Y., & Qian, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113572 · Cited by 286
Wang, X., Li, X., Zhou, J., Lei, Z., & Yang, X. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.110890 · Cited by 40
Metadata
- Authors
- Li, D., Liu, X., Pi, W., Zhang, Y., Yu, L., Xu, C., Sun, Z., & Jiang, J.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-02-22
- Volume
- 12
- Pages
- 808480-808480
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4213208522
- Cited by
- 197
- References
- 10
- FWCI
- 27.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fisetin Attenuates Doxorubicin-Induced Cardiomyopathy In Vivo and In Vitro by Inhibiting Ferroptosis Through SIRT1/Nrf2 Signaling Pathway Activation. https://app.cochat.ai/papers/10.3389/fphar.2021.808480
- The paper
- Li, D., Liu, X., Pi, W., Zhang, Y., Yu, L., Xu, C., Sun, Z., & Jiang, J. (2022). Fisetin Attenuates Doxorubicin-Induced Cardiomyopathy In Vivo and In Vitro by Inhibiting Ferroptosis Through SIRT1/Nrf2 Signaling Pathway Activation. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.808480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.